8JM.F VETOQUINOL INH. EO 250
- Market cap
- EUR 999M
- P/E
- 15.8x
- P/B
- 1.65x
- ROE
- 9.7%
- Dividend yield
- 1.04%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8JM.F undervalued?
Graham number8JM.F trades 7.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VETOQUINOL INH. EO 250 fundamental analysis
No fundamental analysis for VETOQUINOL INH. EO 250 yet.
VETOQUINOL INH. EO 250 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VETOQUINOL INH. EO 250
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in …
Full company profileVETOQUINOL INH. EO 250 financial statements
VETOQUINOL INH. EO 250 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 521M | 540M | 529M | 539M | 526M |
| Gross Profit | 371M | 380M | 373M | 387M | 393M |
| Operating Income | 85.9M | 84.3M | 77.8M | 76.3M | 78.7M |
| EBITDA | - | 116M | 112M | 114M | 116M |
| Net Income | 62.9M | 48.0M | 55.6M | 58.7M | 57.4M |
| EPS | 5.31 | 4.06 | 4.70 | 4.97 | 4.93 |
| Balance Sheet | |||||
| Total Assets | 625M | 652M | 692M | 744M | 764M |
| Total Liabilities | 183M | 167M | 165M | 168M | 172M |
| Shareholders' Equity | 441M | 485M | 527M | 576M | 591M |
| Cash & Short-term Investments | 69.0M | 93.7M | 147M | 206M | 221M |
| Cash Flow | |||||
| Operating Cash Flow | 89.7M | 62.9M | 89.4M | 85.8M | 72.1M |
| Capital Expenditure | 32.4M | 22.5M | 19.0M | 17.7M | 20.7M |
| Free Cash Flow | 57.3M | 40.4M | 70.4M | 68.1M | 51.3M |
| Ratios | |||||
| ROE | 14.2% | 9.9% | 10.5% | 10.2% | 9.7% |
| ROA | 10.1% | 7.4% | 8.0% | 7.9% | 7.5% |
| Net Profit Margin | 12.1% | 8.9% | 10.5% | 10.9% | 10.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
VETOQUINOL INH. EO 250 dividends
- Dividend yield
- 1.04%
- Forward dividend
- 0.93 EUR
- Payout ratio
- 18.1%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 10.4M | 0.89 | 18.1% |
| 2024 | EUR 10.1M | 0.85 | 17.1% |
| 2023 | EUR 9.47M | 0.80 | 17.0% |
| 2022 | EUR 9.47M | 0.80 | 19.7% |
| 2021 | EUR 5.91M | 0.50 | 9.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns VETOQUINOL INH. EO 250
- Insiders 67.01%
- Institutions 10.79%
- Public & others 22.21%
- Shares outstanding 11.6M
- Free float 3.65M
VETOQUINOL INH. EO 250 company profile
- Company name
- VETOQUINOL INH. EO 250
- Ticker
- 8JM.F
- ISIN
- FR0004186856
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,526
- Fiscal year end
- December
- Address
- Magny-Vernois, Lure, France, 70204
- Phone
- 33 3 84 62 55 55
- Website
- vetoquinol.com
About VETOQUINOL INH. EO 250
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.
VETOQUINOL INH. EO 250 management
9- Mr. Matthieu FrechinCEO & Non-Independent Chairman of the Board · born 1969
- Mr. Dominique DerveauxChief Operations Officer & Group Deputy CEO · born 1969
- Mr. Alain MassonDeputy CEO & Pharmacist Manager · born 1962
- Mr. Regis Vimal du MonteilChief Financial Officer · born 1965
- Philippe GruetChief Scientific Officer
- Sandrine PerrierChief Information Officer
- Laurent ThoreDirector of Partnerships, Legal Affairs & Risks
- Xavier BerthetDirector of Group Communications
- Ms. Nathalie ArlecchiniGroup Human Resources Director